… Study Rationale:  Parkinson’s disease (PD) is a complex disorder involving the degeneration of specific brain cells that lead to severe impairments in movement and cognition. Although … the exact cause of PD is not known, several studies have shown that mitochondrial dysfunction is an early and central …

… Rationale:  Abnormal clumping of alpha-synuclein appears to be an important cause for the death of dopamine cells in … of these different alpha-synuclein proteins and compare their modification patterns and quantities. Lastly, … and provide a basis for more specific treatments targeted at the different subtypes of PD. Next Steps for …

… is associated with Parkinson’s disease (PD). Investigators are therefore pursuing the activity of LRRK2 as a potential therapeutic target, for both familial and the more common idiopathic forms of PD. Several approaches to … Biomarkers to Support Therapeutic Trials Program …

… yo yo test hey hey hey …

… which Fox founded in 2000. What's more, it's the first drug to be approved for treatment in which the Fox Foundation … J. Fox Foundation Gets Results." The column discusses how the Foundation's early investments in  Inbrija  -- an … its development to meet an urgent need within the patient community. With this approval and another FDA decision …

… these critical cells would provide a much-needed approach to the treatment of PD. One gene that has been associated … neurodegeneration and therefore presents a potentially targetable for neuroprotection is Atp6v0a. The gene encodes a component of a molecular pump associated with the lysosome, …